The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

Access the Anterior Uveitis Treatment Market Size, Share & Trends Analysis Report By Type (Infectious Uveitis), By Therapy (Biologics), By Distribution Channel (Hospital, Retail, Online Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

Anterior Uveitis Treatment Market Report Highlights

·        Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.

·        Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.

·        Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.

·        Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.

·        Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.

·        North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.

·        Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

Order your free sample copy of “Anterior Uveitis Treatment Market Report 2024 - 2030, published by Grand View Research

Key Anterior Uveitis Treatment Company Insights

Some of the key companies in the Anterior Uveitis Treatment market include Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., Kiora Pharmaceuticals, Inc., Clearside Biomedical, Aldeyra Therapeutics, Inc., UCB S.A., Agilent Technologies, Inc. (Lux Biosciences, Inc)., Tarsier Pharma Ltd. Key manufacturers are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. For instance, in 2024, Kiora Pharmaceuticals, Inc. announced the results from phase I clinical trial of KIO-101 and plans for phase II clinical trial of KIO-104 for intravitreal delivery into the retina for treating posterior non-infectious uveitis.

·        AbbVie Inc. is actively functioning in the eye care segment. It has a wide range of products to treat various ophthalmic conditions. One of the prime products of the company for treating uveitis is “Humira” which is widely accepted as an effective treatment worldwide.

·        Kiora Pharmaceuticals, Inc. is exclusively involved in developing therapies for inherited and inflammatory retinal diseases. There are advanced products present in their pipeline to treat anterior uveitis.

Key Anterior Uveitis Treatment Companies:

The following are the leading companies in the anterior uveitis treatment market. These companies collectively hold the largest market share and dictate industry trends.

·        Novartis AG

·        Santen Pharmaceutical Co., Ltd.

·        AbbVie Inc.

·        Kiora Pharmaceuticals, Inc.

·        Clearside Biomedical

·        Aldeyra Therapeutics, Inc.

·        Aciont Inc.

·        Sirion Therapeutics, Inc.

·        UCB S.A.

·        Lux Biosciences, Inc.

·        Tarsier Pharma Ltd.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  sales@grandviewresearch.com